<DOC>
	<DOCNO>NCT00054249</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness T900607 treat patient gastroesophageal junction cancer .</brief_summary>
	<brief_title>T900607 Treating Patients With Gastroesophageal Junction Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate ( complete partial ) patient previously treat gastric gastroesophageal junction carcinoma treat T900607 . ( Gastric carcinoma close accrual 02/04 . ) - Determine duration response time disease progression patient treat drug . - Determine pharmacokinetics drug patient . - Determine safety profile drug patient . OUTLINE : This open-label , multicenter study . Patients receive T900607 IV 1 hour weekly . Treatment continue absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 20-35 patient accrue study .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm gastric gastroesophageal junction carcinoma ( gastric carcinoma close accrual 02/04 ) Must receive 1 2 prior chemotherapy regimen gastric carcinoma ( gastric carcinoma close accrual 02/04 ) Bidimensionally measurable disease At least 1 lesion least 10 mm CT scan No CNS metastases carcinomatous meningitis PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 70100 % Life expectancy At least 12 week Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3* Platelet count ≥ 100,000/mm^3* Hemoglobin ≥ 8.5 g/dL* NOTE : *Independent growth factor transfusion support Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 3 time ULN INR ≤ 1.5 ( unless receive anticoagulant ) Albumin &gt; 2.5 g/dL Renal Creatinine ≤ 2 time ULN Cardiovascular No New York Heart Association class III IV heart disease LVEF ≥ 50 % No acute anginal symptom Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation Able comply study procedure followup No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix No severe infection No concurrent severe medical condition comorbidity would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy More 7 day since prior growth factor blood transfusion No concurrent therapeutic biological response modifier therapy No concurrent immunotherapy Chemotherapy See Disease Characteristics No concurrent cytotoxic chemotherapy Endocrine therapy No concurrent hormonal therapy Radiotherapy No concurrent radiotherapy ( include palliative radiotherapy ) Surgery More 4 week since prior major surgery Other More 4 week since prior investigational agent No concurrent investigational anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>recurrent gastric cancer</keyword>
</DOC>